SOURCE: Medistem Laboratories

March 20, 2008 08:10 ET

Medistem's Endometrial Regenerative Cell Discovery Publication Receives BioMed Central's Article of the Year Award

SCOTTSDALE, AZ--(Marketwire - March 20, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) is pleased to announce its recent co-authored article entitled, "Endometrial regenerative cells: a novel stem cell population" received BioMed Central's research article of the year in medicine award. The award recognizes excellence in research that has been made universally accessible through open access publication in one of BioMed Central's > 170 peer reviewed scientific journals. The award was presented to Medistem's CEO Thomas Ichim and Dr. Xiaolong Meng at the Royal Society of Medicine in London, England. The publication is freely available at http://www.translational-medicine.com/content/5/1/57.

"We are extremely proud of the international recognition our scientists and collaborators are receiving for the discovery of this new type of stem cell," said Dr. Neil Riordan, President of Medistem. "We believe that these cells, which we have termed endometrial regenerative cells (ERC), offer a novel way of circumventing the medical and ethical issues posed by embryonic stem cells today."

Medistem owns intellectual property associated with endometrial regenerative cells and is currently developing a pipeline of therapeutic products around them. Medistem's lead product is based on preventing amputation through restoring blood flow to the limbs of patients with diabetes and advanced peripheral artery disease.

"The ERC population appears to be superior to other stem cell types. These cells do not require matching with the recipient, they home to areas of injury or tissue damage, and they can become most of the tissue types found in the body," said Dr. Xiaolong Meng, lead author of the article, Associate Director of the Bio-Communications Research Institute, and Medistem collaborator.

About Medistem Laboratories

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. Due to Medistem's relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products. .

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information